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Abstract 
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A liquid chromatography method is reported for the determination of diclofenac potassium and 
its impurities using Quality by Design criteria. Central composite design was used for the 
investigation of the influence of critical parameters on performance that included the methanol 
concentration in the mobile phase, the pH of the aqueous phase, and the potassium dihydrogen 
phosphate concentration in the aqueous phase. Mathematical models enabled theoretical 
examination of experimental space to achieve maximal separation in minimal analysis time. A 
Monte Carlo simulation was used to evaluate the risk of uncertainty in model predictions, to 
adjusting process parameters, and to identify design space. Fractional factorial design was 
employed for robustness testing and method was fully validated. Optimal conditions were a C18 
150 mm  4.6 mm, 5 m particle size column; a methanol – 68.3 mmol L1 potassium 
dihydrogenphosphate (68.7:31.3, v/v) mobile phase at pH 3.0, a flow rate of 1 mL min1, a 
column temperature of 25C, and ultraviolet detection at 254 nm. 
Keywords: design space, diclofenac potassium, impurities, liquid chromatography, Monte Carlo 
simulation, quality by design 
INTRODUCTION 
Nowadays pharmaceutical method development can hardly be imagined without the 
application of Quality by Design concept. Beginning with Food and Drug Administration 
guidance (Food and Drug Administration’s Good Manufacturing Practice for 21st Century), a 
new era in product development in pharmaceutical industry began. This guidance, followed by 
International Conference on Harmonization Q8, gave a new dimension to product development 
and consequently, caused many changes in product development and control. A literature survey 
has shown that there are many papers dealing with Quality by Design approach in method 
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development (Lebrun et al. 2008; Molnár, Rieger, and Monks 2010; Debrus et al. 2011; Monks 
et al. 2012; Cela et al. 2013; Furlanetto et al. 2013; Kormány, Molnár, and Rieger 2013; Mbinze 
et al. 2013; Orlandini, Pinzauti, and Furulanetto 2013; Rozet et al. 2013; Schmidt and Molnár 
2013; Hubert et al. 2014). However, despite the availability of previous studies, development of 
a new method demands separate attention because each mixture possesses special characteristics 
and requires an adjustment of investigation strategy. 
Here the development and validation of a liquid chromatography (LC) method for 
determination of diclofenac potassium and its four impurities is presented. Structures of the 
analytes are presented in Figure 1. The impurities include N-chloroacetyl-N-phenyl-2, 6-
dichloroanilin, 1-(2, 6-dichlophenyl)-2-indolinon, N-phenyl-2,6-dichloranilin, and 2-indolinon 
(1-H-indol-2-ol). 
Many reports have described LC methods for the determination of diclofenac sodium or 
diclofenac potassium and other drugs in pharmaceutical formulations (Ye and Zhang 2000; 
Krzek and Starek 2002; Bisas and Basu 2010; Elkady 2010; Gowramma et al. 2010; Khatal et al. 
2010; Rele et al. 2011; Ambekar, Choudhari, and Ingale 2012; Chaple et al. 2012; Panda, 
Patanaik, and Ravi Kumar 2012; Rubim et al. 2013; Shaalan and Belal 2013; Belal et al. 2014; 
Rubim et al. 2014). Here these impurities were investigated together for the first time. Previous 
papers have considered 1-(2, 6-dichlophenyl)-2-indolinon and 2-indolinon (Krzek and Starek 
2002), while others examined N-chloroacetyl-N-phenyl-2, 6-dichloroanilin and N-phenyl-2, 6-
dichloranilin (Shaalan and Belal 2013; Belal et al. 2014). The Quality by Design approach with 
Monte Carlo simulations allows development of better methods than those without the 
implementation of these approaches. In addition, high-performance thin layer chromatography 
was used for the determination of diclofenac potassium (Ali et al. 2012; Mohite, Potawale, and 
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Gabhe 2013). Also, methods were reported for diclofenac sodium and diclofenac potassium 
determination in biological samples (Lee et al. 2000; Su et al. 2006; BhanuPraksah, VijayaSri, 
and Rama Krishna 2009; Sarfraz, Sarfraz, and Ahmad 2011; Prasad et al. 2012; Sahoo et al. 
2015). A method for diclofenac potassium is available in the European Pharmacopoeia Seventh 
Edition using isocratic conditions with an analysis time of 40 minutes for the determination of 
diclofenac potassium and its impurities. N-Chloroacetyl-N-phenyl-2,6 dichloroanilin and N-
phenyl-2,6-dichloranilin are not presented in the Seventh Edition European Pharmacopoeia, 
although 1-(2, 6-dichlophenyl)-2-indolinon and 2-indolinon(1-H-indol-2-ol) are included. The 
goal of this study was to develop a liquid chromatography method for the determination of 
diclofenac potassium and these four impurities using Quality by Design principles. This is the 
first report involving N-chloroacetyl-N-phenyl-2, 6 dichloroanilin and N-phenyl-2, 6-
dichloranilin with diclofenac potassium and two other impurities. This approach allowed the 
development of reliable and reproductive chromatographic conditions. 
EXPERIMENTAL 
Chemicals and Reagents 
The analytes diclofenac potassium and the impurities (Dipharma Francis s.r.l., Italy) were 
of analytical grade. The mobile phase and the solvents were prepared from methanol (J. T. 
Baker, Neatherlands), potassium dihydrogen phosphate (Sigma; Aldrich, Germany), o -
phosphoric acid (Carlo Erba, Italy), and liquid chromatography grade water. Diclofenac 
potassium tablets were obtained from the local markets. 
Chromatographic Conditions 
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The chromatographic system Waters Breeze included a Waters 1525 Binary HPLC 
Pump, Waters 2487 ultraviolet visible spectroscopy dual absorbance detector, and Breeze 
Software. Separations were performed on the Zorbax Extend XDBC18 150 mm  4.6 mm, 
5 m particle size column (Agilent Technologies, St. Clara, USA). The samples were introduced 
through a Rheodyne injector valve with a 20 L sample loop. The flow rate of the mobile phase 
was 1 mL min1 at 25C with ultraviolet detection at 254 nm. A mixture of methanol–water 
(70:30 v/v) was employed as the solvent. 
Mobile Phase 
The mobile phase consisted of methanol with aqueous potassium dihydrogsen phosphate. 
The mobile phase pH was adjusted with phosphoric acid. The amount of organic solvent, the 
concentration of potassium dihydrogen phosphate in the aqueous phase, and the pH of the mobile 
phase were varied according the experimental design procedure. The mobile phase for the 
optimal chromatographic conditions included methanol and 68.3 mmol L1 potassium 
dihydrogenphosphate in water at 68.7:31.3 (v/v) at pH 3.0. 
Optimization and Robustness 
The stock solution was prepared by dissolving diclofenac potassium and the impurities in 
methanol. The concentration of diclofenac potassium was 1 mg mL1 and of impurities were 
200 μg mL1. In order to obtain working standards, the stock solutions were diluted to 100 μg 
mL1 for diclofenac potassium and 10 μg mL1 for the impurities with solvent. 
Selectivity 
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In order to evaluate the selectivity of the LC method, a placebo mixture was prepared in a 
ratio corresponding to the concentration in the tablets. A standard solution, containing 100 μg 
mL1 of diclofenac potassium and 2 μg mL1 of each impurity, was utilized to characterize the 
selectivity. 
Stock Solutions 
Stock solutions were prepared by dissolving diclofenac potassium and its impurities in 
methanol to obtain 1 mg mL1for diclofenac potassium and 100 μg mL1for the impurities. 
Evaluation of the Linear Dynamic Range 
For the construction of the calibration curve, eight solutions containing diclofenac 
potassium from 25 μg mL1 to 250 μg mL1 were prepared. For impurities, the linearity was 
evaluated using seven solutions across the following concentrations: N-chloroacetyl-N-phenyl-2, 
6-dichloroanilin from 0.5 μg mL1 to 15 μg mL1, 1-(2, 6-dichlophenyl)-2-indolinon from 
0.15 μg mL1 to 10 μg mL1, for N-phenyl-2, 6-dichloranilin from 0.5 μg mL1 to 6 μg mL1, and 
for 2-indolinon (1-H-indol-2-ol) from 0.15 μg mL1 to 5 μg mL1. 
Evaluation of Accuracy 
A solution containing placebo, diclofenac potassium, and its impurities were prepared in 
methanol and sonicated for 10 minutes. This solution was then used for the preparation of 
solutions at 80%, 100% and 120% levels. 
Evaluation of Precision 
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The precision was determined using diclofenac potassium pharmaceutical products 
containing 50 mg of active substance per tablet. The concentrations of impurities were below the 
limit of detection, so the sample was fortified. A tablet mass containing 25 mg of diclofenac 
potassium was fortified with impurities; solvent was added and the solution was sonicated for 
15 minutes. The solution was filtered to obtain 1 mg mL1 and 20 μg mL1 for diclofenac 
potassium and the impurities, respectively. This solution was diluted to provide 200 μg mL1 and 
4 μg mL1 for diclofenac potassium and impurities. This procedure was repeated six times. 
Analysis of Tablets 
A pulverised tablet mass containing 25 mg of diclofenac potassium was extracted with 
25 mL solvent in an ultrasonic bath during 15 min and filtered. This stock solution was used to 
prepare six solutions containing 200 μg mL1 of diclofenac potassium. 
Software 
The experiments for optimization and robustness testing, as well method optimization 
and Design Space definitions were performed in Modde 10.1 (Umetrics, Umea, Sweden). 
RESULTS AND DISCUSSION 
Quality by Design is well-defined in International Conference on Harmonization Q8 and 
is largely complete in the International Conferences on Harmonization Q9 and Q10. General 
characteristics of this approach mean that risk management, scientific knowledge, and improved 
process understanding lead to more efficient and robust response in defined design space. Hence, 
an analytical method was developed that fulfills the criteria defined with this approach. 
Regardless of whether drug is generic or newly synthesized, this approach should be 
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incorporated in method development. Here an LC method was developed for diclofenac 
potassium and its impurities in line with Quality by Design principles. 
Analytical Target Profile and Critical Quality Attributes 
Quality by Design method development starts with definition of analytical target profile 
which is a set of criteria that defines what is measured and the required performance criteria of 
the method denoted as critical quality attributes (Orlandini, Pinzauti, and Furulanetto 2013; 
Rozet et al. 2013). In order to define critical quality attributes, preliminary studies were 
conducted. Taking into account the nature of investigated substances, a C18 column was chosen 
as stationary phase. Some chromatographic factors were set at defined levels at the beginning of 
the study, while other factors such as the organic modifier, aqueous phase composition, and pH 
of the mobile phase were varied. This study has shown that the elution order, 2-indolinon (1-H-
indol-2-ol) before 1-(2, 6-dichlophenyl)-2-indolinon before N-chloroacetyl-N-phenyl-2, 6-
dichloroanilin before diclofenac potassium before N-phenyl-2, 6-dichloranilin, was not affected 
by these changes. Also, methanol concentrations less than 60% caused long run times while 
values higher than 70% influenced the quality of the separation. Consequently, the methanol 
concentration was varied from 60% to 70%. Buffer concentrations from 25 mM to 75 mM were 
employed to evaluate the influence on the separation because small variations did not 
significantly affect the separation. Considering properties of investigated substances, pH values 
from 2.5 to 3.5 were selected for further investigation. 
The main objective of the study was the development of a method for the determination 
of diclofenac potassium and four impurities with maximal separation and minimal analysis time. 
Therefore, the selectivity factor of the critical peak pair, diclofenac potassium and N-phenyl-2, 6-
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dichloranilin, was defined as a critical quality attribute and the goal was to maximize its value. 
The analysis time was characterized as the retention factor of the last eluting peak as the 
retention factor for N-phenyl-2, 6-dichloranilin. Hence this parameter was the second critical 
quality attribute and the goal was to minimize this response. Finally, apart from achieving 
satisfactory values of defined critical quality attributes, the optimal point should be surrounded 
with sufficient design space. In this case, the methanol concentration in the mobile phase, the 
concentration of buffer in mobile phase, and the pH of the mobile phase were defined as critical 
process parameters and were further investigated. 
Knowledge Space and Critical Quality Attribute Modeling 
Critical quality attributes modeling is one of the key steps in Quality by Design 
development and definition of design space. The establishment of mathematical relationships 
between process parameters and important responses allows simulation of chromatographic 
processes and many theoretical experiments without the necessity for real experiments. During 
preliminary experiments, factors and their levels were defined. For deep understanding and 
investigating the influence of those selected factors on important responses, face centered central 
composite design was selected (Massart et al. 1997). The experimental plan defined by the 
applied design is presented in Table 1. 
Experiments were performed randomly and the retention factor for N-phenyl-2, 6-
dichloranilin and the selectivity factor for diclofenac potassium and N-phenyl-2,6-dichloranilin 
were monitored as critical quality attributes. Multiple linear regression and least squares methods 
were applied for creation of mathematical models. The best models for responses were 
investigated. The values of coefficient of determination, adjusted coefficient of determination, 
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and predicted coefficient of determination were applied as indicators of model quality. 
Optimization of the values was done by removal of insignificant model terms. High values of 
coefficient of determination (higher than 0.776) and adjusted coefficient of determination (higher 
than 0.776) suggested that the models adequately fitted the investigated responses. In order to 
visualize the dependence of selected optimization, critical quality attributes on contour plots 
were constructed and presented in Figure 2. 
Design Space and Working Point 
Design space is the most important component of Quality by Design concept and its 
definition is a key part of method development. Design space provides definition of edges of 
failure, outside of which the method performances are not acceptable (Orlandini, Pinzauti, and 
Furulanetto 2013). These edges are defined graphically or by appropriate mathematical equations 
and ensure that the theoretical robustness is acquired within marked region. The method 
operating conditions are not defined as discrete points, but as a working space which decreases 
the chances for method failure (Mbinze et al. 2012). 
The threshold of acceptable values for the selectivity factor of diclofenac potassium and 
N-phenyl-2, 6-dichloranilin was 1.12; for the retention factor of N-phenyl-2, 6-dichloranilin, a 
value of 10 was selected. Sweet spot regions were constructed by overlay of contour plots for 
analyzed responses and are presented in Figure 3. The green area shows where both critical 
quality attributes defined criteria are met, while blue region shows where only one of the criteria 
is met. The large green area provides the surface where the changes of critical process 
parameters do not give variation in critical quality attributes. However, this region does consider 
possible variation in precision of the investigated critical process parameters and model error. 
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Therefore, design space was created applying Monte Carlo simulations and mathematical 
models. This approach allows calculation of the risk of obtaining undesired results for each point 
in knowledge space. 
Once the design space was established, each point within it may be a possible working 
point. It can be selected as point with highest separation quality, or on the basis of practical 
considerations. Also, the optimal point may be selected with the highest probability that critical 
quality attributes are within specifications, i.e., as the most robust point. Here, the most robust 
set point was identified. Therefore, the robust optimization was performed and the working point 
was selected as the one surrounded with the greatest design space. The optimum was at a 
methanol concentration of 68.7% in the mobile phase, a pH value 3.0, and potassium dihydrogen 
phosphate at 68.3 mmol L1. The resulting design space is presented in Figure 4. 
The obtained borders of design space present the region where the changes of critical 
process parameters do not disturb the quality of the method with a probability of 90%. The 
identified critical process parameters ranges were: 65.3% to 72.0% for methanol concentration in 
the mobile phase, 29.83 to 106.83 mmol L1 potassium dihydrogen phosphate in the aqueous 
phase, and pH from 2.5 to 3.5. However, the upper limits for potassium dihydrogen phosphate 
concentration were outside the investigated knowledge space. Therefore, they were corrected to 
the upper border of the knowledge space: 75 mmol L1 for potassium dihydrogen phosphate. The 
optimal conditions were verified experimentally as shown in Figure 5. 
Robustness 
Although design space presents the region of theoretical robustness, robustness testing is 
required for method validation. Therefore, design of experiments methodology was used to 
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explore robustness close to the optimal point. The factors monitored in this phase were the three 
critical process parameters identified in optimization phase and two additional factors: column 
temperature and mobile phase flow rate. The ranges of factor variation were selected to be 
symmetrical around the nominal value. For evaluation of these five factors on robustness, 
fractional factorial design was chosen using 1/4 fraction of full factorial design. The 
experimental plan was set according to fractional factorial design 25–3and is presented in Table 
2. In addition to these experiments, three measurements were performed at the central point. The 
same responses as in the optimization phase were followed. The experiments are performed 
randomly and the results are presented in Table 2. 
The results were evaluated and coefficients for the primary effects are shown in Table 3. 
Statistical evaluation of results obtained from robustness testing was done by the algorithm of 
Dong (Heyden et al. 2001). Obtained Ecritical values are presented in Table 3. Values for factors 
effects for both responses are above the calculated Ecritical, showing the insignificance of all 
factors in robustness testing. 
Validation 
The next step was to perform method validation. Under the optimal conditions, a placebo 
mixture, standards, and a solution for precision estimation were analyzed. There were no 
interferences, confirming the selectivity of the method. The linear dynamic range, accuracy, 
precision, and limits of detection (LOD) and quantification (LOQ) for the analytes were 
determined and obtained results are shown in Table 4. The results for all measurements were 
within the required values (Crowther 2001). 
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The method was employed for the analysis of tablets containing 50 mg of diclofenac 
potassium. The impurities were below the limit of quantification and the determined 
concentration of diclofenac potassium was 99.8% (49.9 mg per tablet). 
CONCLUSIONS 
A liquid chromatography method is reported for diclofenac potassium and four impurities 
in accordance with Quality by Design. The importance of this strategy in modern pharmaceutical 
analysis is emphasized and each step of the process is described in detail. Special attention was 
devoted to design of experiments for creation of reliable mathematical models. The study 
provided optimal chromatographic conditions for diclofenac potassium and its impurities in a 
well-defined, robust region. The method was validated and used for the analysis of real samples 
to verify the applicability of the method. 
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Table 1. Face centered central composite design, retention factor for N-phenyl-2, 6-
dichloranilin, and selectivity factor for diclofenac potassium and N-phenyl-2, 6-dichloranilin 
Experiment Factor Response 
A B C Retention 
factor for N-
phenyl-2, 6-
dichloranilin 
Selectivity factor for 
diclofenac potassium 
and N-phenyl-2, 6-
dichloranilin 
Methanol 
concentration 
(%) 
Mobile 
phase 
pH 
Buffer 
concentration 
(mM) 
1 60 (1)* 2.5 
(1) 
25 (1) 17.21 1.1 
2 70 (+1) 2.5 
(1) 
25 (1) 6.71 1.12 
3 60 (1) 3.5 
(+1) 
25 (1) 19.56 1.1 
4 70 (+1) 3.5 
(+1) 
25 (1) 5.99 1.12 
5 60 (1) 2.5 
(1) 
75 (+1) 23.37 1.07 
6 70 (+1) 2.5 
(1) 
75 (+1) 6.96 1.16 
7 60 (1) 3.5 
(+1) 
75 (+1) 18.41 1.11 
8 70 (+1) 3.5 75 (+1) 6.29 1.17 
 18 
(+1) 
9 60 (1) 3.0 (0) 50 (0) 23.22 1.07 
10 70 (+1) 3.0 (0) 50 (0) 7.03 1.17 
11 65 (0) 2.5 
(1) 
50 (0) 12.5 1.14 
12 65 (0) 3.5 
(+1) 
50 (0) 10.4 1.14 
13 65 (0) 3.0 (0) 25 (1) 11.92 1.12 
14 65 (0) 3.0 (0) 75 (+1) 11.79 1.13 
15 65 (0) 3.0 (0) 50 (0) 11.95 1.14 
16 65 (0) 3.0 (0) 50 (0) 11.82 1.13 
17 65 (0) 3.0 (0) 50 (0) 10.94 1.12 
*Coded values are in parentheses. 
 19 
Table 2. Robustness characterized by fractional factorial design 25–2, retention factor for N-
phenyl-2, 6-dichloranilin, and selectivity factor for diclofenac potassium and N-phenyl-2, 6-
dichloranilin 
Experime
nt 
Methanol 
concentrati
on (%) 
Buffer 
concentrati
on (mM) 
Mobil
e 
phase 
pH 
Column 
temperatur
e (C) 
Flow 
rate 
(mL 
min1
) 
Retention 
factor for 
N-phenyl-
2, 6-
dichloranili
n 
Selectivity 
factor for 
diclofenac 
potassium 
and N-
phenyl-2, 
6-
dichloranili
n 
1 66.7 63.3 2.8 27 1.1 5.886 1.177 
2 70.7 63.3 2.8 23 0,9 7.565 1.18 
3 66.7 73.3 2.8 27 1.1 6.517 1.146 
4 70.7 73.3 2.8 23 0.9 6.429 1.179 
5 66.7 63.3 3.2 27 1.1 9.728 1.161 
6 70.7 63.3 3.2 23 0.9 6.104 1.142 
7 66.7 73.3 3.2 27 1.1 11.672 1.17 
8 70.7 73.3 3.2 23 0.9 5.23 1.186 
9 68.7 68.3 3.0 25 1.0 7.272 1.151 
10 68.7 68.3 3.0 25 1.0 6.997 1.155 
11 68.7 68.3 3.0 25 1.0 7.022 1.157 
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Table 3. Coefficients from the mathematical models for robustness and their statistical 
significance 
Coefficient Response 
Retention factor for N-
phenyl-2, 6-dichloranilin 
Selectivity factor for diclofenac 
potassium and N-phenyl-2, 6-
dichloranilin 
Constant 3.9463 76.9865 
Methanol content (%) 0.57177 0.2728 
Buffer concentration 
(mM) 
0.03806 0.1736 
pH of the mobile phase 0.4274 0.1901 
Column temperature 
(C) 
0.3092 0.5374 
Flow rate (mL min1) 0.7865 0.3224 
Ecritical calculated 
according to Heyden et 
al. (2001) 
1.2727 0.7790 
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Table 4. Analytical figures of merit 
Parameter Diclofena
c 
potassium 
N-
Chloroacetyl
-N-phenyl-2, 
6-
dichloroanili
n 
1-(2, 6-
Dichlophenyl)
-2-indolinon 
N-Phenyl-2, 
6-
dichloranili
n 
2-
Indolino
n (1-H-
indol-2-
ol) 
 Linear 
dynamic 
range (g 
mL1) 
25–250 0.5–15 0.15–10 0.5–6 0.15–5 
Slope 21.734 23.77 28.708 19.5755 72.29 
Intercept 47.9324 0.3405 1.1594 4.3304 6.798 
Correlation 
coefficient 
0.9997 0.9998 0.9991 0.9939 0.9991 
p-value 0.1375 0.813 0.6946 0.357 0.1302 
Limit of 
Quantificatio
n 
 0.5 0.15 0.5 0.13 
Limit of 
Detection 
0.15 0.04 0.15 0.08 
Accurac
y as the 
80% 98.9 98.8 101.3 103.9 101.2 
100% 99.7 96.7 103.7 100.1 98.9 
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Recover
y (%) 
120% 97.2 97.5 106.9 99.1 97.9 
Precisio
n 
Relative 
Standard 
Deviation 
(%) 
1.5 1.4 1.93 1.84 1.9 
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Figure 1. Analytes. 
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Figure 2. Contour plots for the (A) retention factor for N-phenyl-2, 6-dichloranilin obtained by 
plotting methanol concentration in the mobile phase as a function potassium hydrogen phosphate 
concentration at pH 3.0 and (B) selectivity factor for diclofenac potassium and N-phenyl-2, 6-
dichloranilin obtained by plotting methanol concentration in the mobile phase as a function of 
potassium hydrogen phosphate concentration at pH 3.0. 
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Figure 3. Sweet spot plots obtained by plotting methanol concentration in the mobile phase as a 
function of potassium hydrogen phosphate concentration in the aqueous phase at pH 3.0 defined 
by the selectivity factor for diclofenac potassium and N-phenyl-2, 6-dichloranilin >1.12 and the 
retention factor for N-phenyl-2, 6-dichloranilin <10. Regions where only one criterion was met 
are blue; regions where both criteria were met are green. 
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Figure 4. Design space for the separation of diclofenac potassium and its impurities for 
methanol and potassium hydrogen phosphate concentrations in the aqueous phase at pH 3.0. 
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Figure 5. Chromatogram of diclofenac potassium and its impurities under the optimal 
conditions: (1) 2-indolinon (1-H-indol-2-ol), (2) 1-(2, 6-dichlophenyl)-2-indolinon, (3) N-
chloroacetyl-N-phenyl-2, 6-dichloroanilin, (4) diclofenac potassium, and (5) N-phenyl-2, 6-
dichloranilin. 
 
 
 
 
